Previously, following quality control of medicinal products at manufacturing sites in France, we were required to obtain additional quality certificates from local laboratories in Russia, as the format of the manufacturers’ certificates did not meet the requirements of the Russian Federal Service for Surveillance in Healthcare (Roszdravnadzor).

In 2026, following registration of all our products under the EAEU regulations and the update of certificates in accordance with new requirements, we were able to eliminate this additional step.
At the same time, the key principle remains unchanged: the manufacturer continues to carry out full quality control.

As a result, the product market release has accelerated by 2–5 working day, enabling the company to save RUB 4 million annually.
Fewer steps — faster results — greater efficiency
No comments yet, be the first to comment.